AAPL316.22-3.75 (-1.17%) ▼|ABBV248.78-7.68 (-2.99%) ▼|ABT105.52-2.81 (-2.59%) ▼|ACN179.03-7.69 (-4.12%) ▼|ADBE257.26-9.25 (-3.47%) ▼|AMAT472.79+18.08 (+3.98%) ▲|AMD505.74+28.17 (+5.90%) ▲|AMGN393.17-44.06 (-10.08%) ▼|AMT175.73-0.12 (-0.07%) ▼|AMZN256.97-1.54 (-0.60%) ▼|AVGO368.56+10.67 (+2.98%) ▲|AXP326.10-0.06 (-0.02%) ▼|BA210.73-1.52 (-0.72%) ▼|BAC62.39-0.29 (-0.46%) ▼|BKNG180.30-12.99 (-6.72%) ▼|BLK1,095.37-21.19 (-1.90%) ▼|BMY64.69-2.13 (-3.19%) ▼|BNY162.85-1.99 (-1.21%) ▼|BRK-B505.83-0.20 (-0.04%) ▼|C136.74-0.98 (-0.71%) ▼|CAT822.48+8.54 (+1.05%) ▲|CL88.41-0.36 (-0.41%) ▼|CMCSA26.33-0.16 (-0.60%) ▼|COF213.96-5.64 (-2.57%) ▼|COP135.04+0.78 (+0.58%) ▲|COST910.18-5.56 (-0.61%) ▼|CRM249.12-10.11 (-3.90%) ▼|CSCO109.17-0.03 (-0.03%) ▼|CVS96.07-0.67 (-0.69%) ▼|CVX209.80+1.20 (+0.58%) ▲|DE680.73-12.80 (-1.85%) ▼|DHR205.23-2.43 (-1.17%) ▼|DIS105.06-0.25 (-0.24%) ▼|DUK121.24+1.02 (+0.85%) ▲|EMR152.15-0.67 (-0.44%) ▼|FDX314.13-8.39 (-2.60%) ▼|GD356.58-2.81 (-0.78%) ▼|GE334.91-2.21 (-0.66%) ▼|GEV971.31+29.36 (+3.12%) ▲|GILD146.64-4.36 (-2.88%) ▼|GM85.79-1.97 (-2.24%) ▼|GOOG335.38+0.07 (+0.02%) ▲|GOOGL338.36-0.10 (-0.03%) ▼|GS1,036.53-2.08 (-0.20%) ▼|HD313.70-7.35 (-2.29%) ▼|HON208.24-1.37 (-0.65%) ▼|IBM232.09-2.80 (-1.19%) ▼|INTC104.47+8.67 (+9.05%) ▲|INTU318.93-13.77 (-4.14%) ▼|ISRG350.16-16.54 (-4.51%) ▼|JNJ269.12-6.11 (-2.22%) ▼|JPM353.51-5.13 (-1.43%) ▼|KO88.36+0.29 (+0.33%) ▲|LIN468.38-9.19 (-1.92%) ▼|LLY1,123.91-25.45 (-2.21%) ▼|LMT536.15+10.87 (+2.07%) ▲|LOW200.80-3.65 (-1.79%) ▼|LRCX320.42+12.77 (+4.15%) ▲|MA570.89-8.32 (-1.44%) ▼|MCD255.81+0.12 (+0.05%) ▲|MDLZ61.63+0.35 (+0.57%) ▲|MDT92.39-1.78 (-1.89%) ▼|META613.48-3.29 (-0.53%) ▼|MMM167.52-1.04 (-0.62%) ▼|MO68.17-0.71 (-1.03%) ▼|MRK148.46-1.87 (-1.24%) ▼|MS216.24-1.48 (-0.68%) ▼|MSFT493.95-5.75 (-1.15%) ▼|MU1,000.26-16.33 (-1.61%) ▼|NEE83.83+0.40 (+0.48%) ▲|NFLX76.77-1.48 (-1.89%) ▼|NKE38.10-0.30 (-0.78%) ▼|NOW134.21-7.05 (-4.99%) ▼|NVDA225.73-4.63 (-2.01%) ▼|ORCL162.52+3.74 (+2.36%) ▲|PEP138.45+0.82 (+0.60%) ▲|PFE27.79-0.66 (-2.32%) ▼|PG145.58-0.86 (-0.59%) ▼|PLTR170.30-4.03 (-2.31%) ▼|PM184.73+2.20 (+1.21%) ▲|QCOM174.09+5.35 (+3.17%) ▲|RTX198.81-1.98 (-0.99%) ▼|SBUX102.01-2.46 (-2.35%) ▼|SCHW106.87-2.42 (-2.21%) ▼|SO88.99+0.88 (+1.00%) ▲|SPG211.88+2.44 (+1.17%) ▲|T25.60-0.08 (-0.31%) ▼|TMO603.02-10.76 (-1.75%) ▼|TMUS181.69+0.17 (+0.09%) ▲|TSLA368.16+14.08 (+3.98%) ▲|TXN258.92+0.48 (+0.19%) ▲|UBER73.13-2.63 (-3.47%) ▼|UNH400.84+3.70 (+0.93%) ▲|UNP288.45-1.17 (-0.40%) ▼|UPS100.48-1.81 (-1.77%) ▼|USB62.49-0.88 (-1.39%) ▼|V368.64-6.43 (-1.71%) ▼|VZ50.41+0.27 (+0.54%) ▲|WFC87.96-2.01 (-2.23%) ▼|WMT106.05-1.09 (-1.02%) ▼|XOM160.66+1.19 (+0.75%) ▲|AAPL316.22-3.75 (-1.17%) ▼|ABBV248.78-7.68 (-2.99%) ▼|ABT105.52-2.81 (-2.59%) ▼|ACN179.03-7.69 (-4.12%) ▼|ADBE257.26-9.25 (-3.47%) ▼|AMAT472.79+18.08 (+3.98%) ▲|AMD505.74+28.17 (+5.90%) ▲|AMGN393.17-44.06 (-10.08%) ▼|AMT175.73-0.12 (-0.07%) ▼|AMZN256.97-1.54 (-0.60%) ▼|AVGO368.56+10.67 (+2.98%) ▲|AXP326.10-0.06 (-0.02%) ▼|BA210.73-1.52 (-0.72%) ▼|BAC62.39-0.29 (-0.46%) ▼|BKNG180.30-12.99 (-6.72%) ▼|BLK1,095.37-21.19 (-1.90%) ▼|BMY64.69-2.13 (-3.19%) ▼|BNY162.85-1.99 (-1.21%) ▼|BRK-B505.83-0.20 (-0.04%) ▼|C136.74-0.98 (-0.71%) ▼|CAT822.48+8.54 (+1.05%) ▲|CL88.41-0.36 (-0.41%) ▼|CMCSA26.33-0.16 (-0.60%) ▼|COF213.96-5.64 (-2.57%) ▼|COP135.04+0.78 (+0.58%) ▲|COST910.18-5.56 (-0.61%) ▼|CRM249.12-10.11 (-3.90%) ▼|CSCO109.17-0.03 (-0.03%) ▼|CVS96.07-0.67 (-0.69%) ▼|CVX209.80+1.20 (+0.58%) ▲|DE680.73-12.80 (-1.85%) ▼|DHR205.23-2.43 (-1.17%) ▼|DIS105.06-0.25 (-0.24%) ▼|DUK121.24+1.02 (+0.85%) ▲|EMR152.15-0.67 (-0.44%) ▼|FDX314.13-8.39 (-2.60%) ▼|GD356.58-2.81 (-0.78%) ▼|GE334.91-2.21 (-0.66%) ▼|GEV971.31+29.36 (+3.12%) ▲|GILD146.64-4.36 (-2.88%) ▼|GM85.79-1.97 (-2.24%) ▼|GOOG335.38+0.07 (+0.02%) ▲|GOOGL338.36-0.10 (-0.03%) ▼|GS1,036.53-2.08 (-0.20%) ▼|HD313.70-7.35 (-2.29%) ▼|HON208.24-1.37 (-0.65%) ▼|IBM232.09-2.80 (-1.19%) ▼|INTC104.47+8.67 (+9.05%) ▲|INTU318.93-13.77 (-4.14%) ▼|ISRG350.16-16.54 (-4.51%) ▼|JNJ269.12-6.11 (-2.22%) ▼|JPM353.51-5.13 (-1.43%) ▼|KO88.36+0.29 (+0.33%) ▲|LIN468.38-9.19 (-1.92%) ▼|LLY1,123.91-25.45 (-2.21%) ▼|LMT536.15+10.87 (+2.07%) ▲|LOW200.80-3.65 (-1.79%) ▼|LRCX320.42+12.77 (+4.15%) ▲|MA570.89-8.32 (-1.44%) ▼|MCD255.81+0.12 (+0.05%) ▲|MDLZ61.63+0.35 (+0.57%) ▲|MDT92.39-1.78 (-1.89%) ▼|META613.48-3.29 (-0.53%) ▼|MMM167.52-1.04 (-0.62%) ▼|MO68.17-0.71 (-1.03%) ▼|MRK148.46-1.87 (-1.24%) ▼|MS216.24-1.48 (-0.68%) ▼|MSFT493.95-5.75 (-1.15%) ▼|MU1,000.26-16.33 (-1.61%) ▼|NEE83.83+0.40 (+0.48%) ▲|NFLX76.77-1.48 (-1.89%) ▼|NKE38.10-0.30 (-0.78%) ▼|NOW134.21-7.05 (-4.99%) ▼|NVDA225.73-4.63 (-2.01%) ▼|ORCL162.52+3.74 (+2.36%) ▲|PEP138.45+0.82 (+0.60%) ▲|PFE27.79-0.66 (-2.32%) ▼|PG145.58-0.86 (-0.59%) ▼|PLTR170.30-4.03 (-2.31%) ▼|PM184.73+2.20 (+1.21%) ▲|QCOM174.09+5.35 (+3.17%) ▲|RTX198.81-1.98 (-0.99%) ▼|SBUX102.01-2.46 (-2.35%) ▼|SCHW106.87-2.42 (-2.21%) ▼|SO88.99+0.88 (+1.00%) ▲|SPG211.88+2.44 (+1.17%) ▲|T25.60-0.08 (-0.31%) ▼|TMO603.02-10.76 (-1.75%) ▼|TMUS181.69+0.17 (+0.09%) ▲|TSLA368.16+14.08 (+3.98%) ▲|TXN258.92+0.48 (+0.19%) ▲|UBER73.13-2.63 (-3.47%) ▼|UNH400.84+3.70 (+0.93%) ▲|UNP288.45-1.17 (-0.40%) ▼|UPS100.48-1.81 (-1.77%) ▼|USB62.49-0.88 (-1.39%) ▼|V368.64-6.43 (-1.71%) ▼|VZ50.41+0.27 (+0.54%) ▲|WFC87.96-2.01 (-2.23%) ▼|WMT106.05-1.09 (-1.02%) ▼|XOM160.66+1.19 (+0.75%) ▲|
21.6 C
New York
Wednesday, September 9, 2026

Tag: patient

newssourceFORcompanyinformationcontent1releasesmarket

Registration Opens for JADPRO Live 2026: Advanced Practitioners Gather in the Heartland to Champion High-Quality Cancer Care

The annual JADPRO Live conference for oncology advanced practitioners will take place this year from October 15 through 18 at the Minneapolis Convention Center...

RoenRx Releases 2026 Weight-Loss Program Pricing and Treatment Cost Overview

New York, NY, June 23, 2026 (GLOBE NEWSWIRE) -- RoenRx, a telehealth platform providing medically supervised weight-loss care, today released updated 2026 pricing information for its weight-loss program, detailing membership costs, insurance-supported GLP-1 treatment options, compounded medication pricing, bundled care plans, and subscription terms. The pricing overview is intended to provide prospective patients with greater transparency regarding the potential costs associated with RoenRx's weight-management services and available treatment pathways.

Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication

Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD 
Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

SKYRIZI® (risankizumab) expands its indication for children and adolescents six years of age and older with moderate to severe plaque psoriasis1Approval was based on...

Curaleaf International Launches CPD-Accredited Medical Cannabis Education Platform for UK Healthcare Professionals

LONDON, June 23, 2026 /PRNewswire/ -- Curaleaf International, one of the global leaders in medical cannabis, today announces the launch of the Curaleaf Education...

SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting

Shareholders adopt all proposals, co-founder Dr. Jurgi Camblong elected as Executive Chairman of the Board, Ross Muken elected as new member of the Board...

DermDox Group Expands Aesthetic and Surgical Capabilities Through Acquisition of Modern Aesthetics Plastic Surgery

Adding to its expansion in the Mid-Atlantic regionNEWTOWN, Pa., June 22, 2026 /PRNewswire/ -- DermDox Group, a leading provider of medical, surgical, and aesthetic...

Questex’s DPHARM Announces Senior Leadership and Keynotes for the 16th Annual Conference

BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- DPHARM, the leading innovation event for clinical trial operation executives, announces the 16th annual conference agenda including its senior leadership and keynotes. DPHARM which is now part of Questex’s Fierce Life Sciences, takes place September 15-16, 2026, at the Sheraton Boston Hotel.

Karmanos Cancer Institute Reaches Historic Growth Milestone, Positioning Itself as a Leader in Oncology Care Delivery

Unprecedented patient demand reflects a deliberate strategy focused on access, advanced therapies and integrated researchDETROIT, June 22, 2026 /PRNewswire/ -- The Barbara Ann Karmanos Cancer...

Nura Bio Completes $73.8M Series B Financing and Advances Pipeline of SARM1 Inhibitors

Nura Bio announced the completion of a Series B financing and the advancement of its two clinical-stage SARM1 inhibitor programs

Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell

— The study shows that EGFR-TKIs induce TROP2 upregulation in DTP cells, providing a mechanistic basis for combining sac-TMT with EGFR-TKI.— The Company is...

Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders

CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a...

Pharmacy automation interoperability: Deenova to deliver an integrated medication management platform at Policlinico di Milano

Pharmacy automation interoperability: Deenova to deliver an integrated medication management platform at Policlinico di Milano.

FDA Clears PanopticAI’s Contactless Respiratory Rate Measurement

Following the startup's first FDA 510 (k) clearance for its contactless pulse rate monitoring, PanopticAI has now secured a second one for respiratory rate...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatient

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers